Invest in a Prescription Medicine Breakthrough

$10.00

$750

Series A Convertible Cumulative Preferred Shares

Redemption Feature
Commencing on the fifth anniversary of the initial closing of this offering and continuingindefinitely thereafter, we shall have a right to call for redemption the outstanding shares of our Series A Preferred Stock at a call price equal to 150% of the original issue price of our Series A Preferred Stock, and correspondingly, each holder of shares of our Series A Preferred Stock shall have a right to put the shares of Series A Preferred Stock held by such holder back to us at a put price equal to 150% of the original issue purchase price of such shares. The Series A Preferred Stock will have no voting rights (except for certain limited matters described further in the offering circular).

Conversion Feature

Each share of the Series A Preferred Stock is convertible into twenty (20) shares of our Common Stock at the option of the holder. Our common shares trade on the TSX: IGX and OTCQB:IGXT

Up to $20M

Holders of our Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter which is an 8% rate.

New product launches, working capital and debt repayment.

Holders of our Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter, which is equivalent to the annual rate of 8.00% of the $10.00 purchase price per share; provided that upon an event of default (generally defined as our failure to pay dividends when due or to redeem shares when requested by a holder), such amount shall be increased to $0.30 per quarter, which is equivalent to the annual rate of 12% of the $10.00 purchase price per share.

Each holder of the Series A Preferred Stock is entitled to convert any of the outstanding shares of Series A Preferred Stock held by such holder into validly issued, fully paid and non-assessable shares of our Common Stock. Each share of the Series A Preferred Stock is convertible into our Common Stock at the conversion rate of 1 share of Series A Preferred Stock to 20 shares of Common Stock, subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock.

In certain exit opportunities you could convert your shares into cash or a more liquid asset. Exits include getting acquired by a larger company, or our company buying back shares. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by IntelGenx are highly speculative. Investing in shares of IntelGenx involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

IntelGenx intends to list the Preferred Stock offered under this Form 1-A on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.

Shares will be allocated after the investment funds clear. This typically takes around 3weeks after investment which shall be held directly with our transfer agent Pacific StockTransfer Company, 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119, Tel. 702-361-3033.

No, costs are the same, regardless of how you invest

Although there is no guarantee that the market will be receptive to products incorporating our drug delivery technologies, the company has demonstrated considerable traction, reassuring investors of its market potential. They have forged strategic partnerships with major players in the pharmaceutical and cannabis industries, like atai Life Sciences and Gensco Pharma, lending credibility and market access. A pivotal achievement is the FDA approval of their migraine product, Rizafilm, a testament to the product's efficacy and safety. Their state-of-the-art manufacturing facility is ready to meet large-scale production demands, vital for market supply. With a diverse range of products targeting substantial markets such as migraines, erectile dysfunction, Pain, Alzheimer's, and Parkinson's diseases, the company diversifies its market risk. Additionally, initial purchase orders from companies like Tilray for their cannabis products indicate immediate market interest, and plans to start commercial sales of Versafilm in 2024 further underscore their market readiness and potential for revenue growth. These elements collectively offer investors a clear picture of the company's strong market position and promising future sales prospects.

We believe that the growth potential for this company is promising and the company may be positioned to expand their market reach significantly, thanks to their innovative thin film technology and a diverse product range targeting key health areas. Their active development pipeline, focused on conditions like Alzheimer's, Parkinson's, Animal Health and applications in cannabis, signals ongoing innovation and relevance in the pharmaceutical industry. Strategic partnerships with major players could offer immediate market access and potential for future expansion. The company's success in securing FDA approval showcases their ability to navigate global regulatory landscapes, opening doors to international markets. Additionally, the rising demand for user-friendly drug delivery systems, coupled with their ability to repurpose well-known drugs for new uses, should offer a faster route to market expansion. Additionally, we believe their robust manufacturing and distribution capabilities should help them meet any increasing demand efficiently. All these factors combined suggest a strong trajectory for potential growth and expansion in the coming years.

Investing in this company may offer a unique opportunity to be part of a potential pioneering shift in pharmaceuticals. Their cutting-edge thin film technology can simplify medication intake, making it easier, faster, and more efficient than many traditional methods. We believe this innovation is not just a step forward in patient convenience and compliance but also enhances the effectiveness of medications. The company's diverse portfolio, including successful ventures into the growing markets of migraines, erectile dysfunction, Pain, Alzheimer's, and Parkinson's disease treatments, as well as cannabis, indicates a broad and scalable application of their technology. Additionally, the company's solid partnerships with established pharmaceutical and cannabis companies, recent FDA approvals, and a robust pipeline of products in various stages of development and commercialization could further solidify its investment potential. We believe this combination of innovative technology, strategic partnerships, and market-ready solutions positions the company as an attractive investment opportunity in a lucrative pharmaceutical industry.